Evidence map›Paper›PMID 32106025›Full record

ArticleNeuroImage. Clinical2020

Modelling prognostic trajectories of cognitive decline due to Alzheimer's disease.

Joseph Giorgio, Susan M Landau, William J Jagust, Peter Tino, Zoe Kourtzi, Alzheimer's Disease Neuroimaging Initiative

Open access · goldAbstract read
In one paragraph

Article in NeuroImage. Clinical, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 38 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
38citing papers in PubMed, 2 pooled it
8.6field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

38 citing papers in PubMed, 2 syntheses or guidelines pooled it, 79 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Article
  4. Solving the 'Goldilocks problem' in dementia clinical trials with multimodal AI.The journal of prevention of Alzheimer's disease · 2025
    Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Artificial intelligence for biomarker discovery in Alzheimer's disease and dementia.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2023
    Review
  13. Article
  14. Article
  15. How can secondary dementia prevention trials of Alzheimer's disease be clinically meaningful?Alzheimer's & dementia : the journal of the Alzheimer's Association · 2023
    Article
  16. Review
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 3 institutions in 2 countries.

Joseph GiorgioDepartment of Psychology, University of Cambridge, Cambridge, United Kingdom.
Susan M LandauHelen Wills Neuroscience Institute, University of California, Berkeley, CA USA.
William J JagustHelen Wills Neuroscience Institute, University of California, Berkeley, CA USA.
Peter TinoSchool of Computer Science, University of Birmingham, Birmingham, United Kingdom.
Zoe KourtziDepartment of Psychology, University of Cambridge, Cambridge, United Kingdom. Electronic address: zk240@cam.ac.uk.
Alzheimer's Disease Neuroimaging Initiative
University of California, Berkeley · USUniversity of Cambridge · GBUniversity of Birmingham · GB

Funding

Alzheimer's Disease Neuroimaging Initiative - SupplementU01AG024904 · NIA · NORTHERN CALIFORNIA INSTITUTE RES &EDUC · PI WEINER, MICHAEL W · 2004 to 2015
$121.0M
Neural and Biochemical Mechanisms of Cognitive AgingR01AG034570 · NIA · UNIVERSITY OF CALIF-LAWRENC BERKELEY LAB · PI William J. Jagust · 2009 to 2026
$12.0M
Biotechnology and Biological Sciences Research Council BB/H012508/1Biotechnology and Biological Sciences Research Council BB/P021255/1Biotechnology and Biological Sciences Research Council H012508NIA NIH HHS U01 AG024904Wellcome Trust 205067/Z/16/Z
6 · The paper itself

Abstract

Alzheimer's disease (AD) is characterised by a dynamic process of neurocognitive changes from normal cognition to mild cognitive impairment (MCI) and progression to dementia. However, not all individuals with MCI develop dementia. Predicting whether individuals with MCI will decline (i.e. progressive MCI) or remain stable (i.e. stable MCI) is impeded by patient heterogeneity due to comorbidities that may lead to MCI diagnosis without progression to AD. Despite the importance of early diagnosis of AD for prognosis and personalised interventions, we still lack robust tools for predicting individual progression to dementia. Here, we propose a novel trajectory modelling approach based on metric learning (Generalised Metric Learning Vector Quantization) that mines multimodal data from MCI patients in the Alzheimer's disease Neuroimaging Initiative (ADNI) cohort to derive individualised prognostic scores of cognitive decline due to AD. We develop an integrated biomarker generation- using partial least squares regression- and classification methodology that extends beyond binary patient classification into discrete subgroups (i.e. stable vs. progressive MCI), determines individual profiles from baseline (i.e. cognitive or biological) data and predicts individual cognitive trajectories (i.e. change in memory scores from baseline). We demonstrate that a metric learning model trained on baseline cognitive data (memory, executive function, affective measurements) discriminates stable vs. progressive MCI individuals with high accuracy (81.4%), revealing an interaction between cognitive (memory, executive functions) and affective scores that may relate to MCI comorbidity (e.g. affective disturbance). Training the model to perform the same binary classification on biological data (mean cortical β-amyloid burden, grey matter density, APOE 4) results in similar prediction accuracy (81.9%). Extending beyond binary classifications, we develop and implement a trajectory modelling approach that shows significantly better performance in predicting individualised rate of future cognitive decline (i.e. change in memory scores from baseline), when the metric learning model is trained with biological (r = -0.68) compared to cognitive (r = -0.4) data. Our trajectory modelling approach reveals interpretable and interoperable markers of progression to AD and has strong potential to guide effective stratification of individuals based on prognostic disease trajectories, reducing MCI patient misclassification, that is critical for clinical practice and discovery of personalised interventions.

Indexed as

Machine LearningAgedAlzheimer DiseaseBrainCognitive DysfunctionDisease ProgressionFemaleHumansImage Interpretation, Computer-AssistedMagnetic Resonance ImagingMaleMiddle AgedModels, NeurologicalNeuroimagingPrognosisAlzheimer's disease brain imagingCognitionMachine learningMild cognitive impairment

Identifiers

PMID32106025
PMCPMC7044529
OpenAlexW3002204673

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.